Blueprint Medicines Corp Stock Widgets and Gadgets
| BPMC Stock | USD 92.26 0.03 0.03% |
| Intraday Equity Chart Quick Equity Feed Equity Search Quote Ticker Widgets Data Sheet |
Live Stock Ticker Example
- BPMC Blueprint Medicines Corp
- Latest Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray
- BPMC 92.26 -0.03
- Low 90.43
- High 93.74
- Volume 588.5 K
- Alpha 0.00499
- Beta 2.76
- Return On Equity -1.57
- Return On Asset -0.25
- Profit Margin (2.03) %
- Operating Margin (1.46) %
- Current Valuation 5.71 B
- Shares Outstanding 61.23 M
- Shares Owned By Insiders 0.85 %
- Shares Owned By Institutions 99.15 %
- Number Of Shares Shorted 4.37 M
- Price To Earning 7.93 X
- Price To Book 40.90 X
- Price To Sales 21.42 X
- Revenue 249.38 M
- Gross Profit 177.28 M
- EBITDA (474.61 M)
- Net Income (506.98 M)
- Cash And Equivalents 853.11 M
- Cash Per Share 14.28 X
- Total Debt 774.12 M
- Debt To Equity 0.14 %
- Current Ratio 6.00 X
- Book Value Per Share 2.14 X
- Cash Flow From Operations (436.85 M)
- Short Ratio 5.37 X
- Earnings Per Share (8.37) X
- Target Price 97.38
- Number Of Employees 655
- Beta 0.65
- Market Capitalization 5.61 B
- Total Asset 1.05 B
- Retained Earnings (2.34 B)
- Working Capital 593.47 M
- Current Asset 170.42 M
- Current Liabilities 18.64 M
- Net Asset 1.05 B
- Accumulation Distribution 20781.6
- Daily Balance Of Power (0.01)
- Rate Of Daily Change 1.0
- Day Median Price 92.09
- Day Typical Price 92.14
- Price Action Indicator 0.16
- Period Momentum Indicator (0.03)
- Relative Strength Index 49.1
Market Snapshot Widget Example
DAX Index Germany | 18,089 0.27 | |
Taiwan Weighted Taiwan | 20,132 2.72 | |
PSI 20 Stock Portugal | 6,530 0.95 | |
CROBEX Croatia | 2,786 0.05 | |
Budapest SE Hungary | 66,377 0.66 | |
IDX 30 Jakarta Indonesia | 472.42 0.44 | |
ISEQ 20 Price Ireland | 1,652 0.95 | |
NYSE Comp USA | 17,758 0.19 | |
Tel Aviv 35 Israel | 1,938 1.13 | |
Coreshares Index Tracker South Afric | 1,056 1.44 | |
IPC MEXICO Mexico | 56,464 0.3 | |
KL Technology Malaysia | 64.16 1.55 | |
IBEX 35 Index Spain | 11,028 0.43 | |
SP Merval Argentina | 1,000,000 0.00 | |
Austrian Traded Index Austria | 3,580 0.02 | |
SPASX Dividend Opportunities Australia | 1,657 0.08 | |
HNX 30 Vietnam | 481.21 2.05 | |
Bucharest BET-NG Romania | 1,202 0.1 | |
AMS Small Cap Netherlands | 1,189 1.29 | |
Oslo Exchange Mutual Norway | 1,304 1.04 | |
BEL Small Belgium | 9,020 0.03 | |
RTSI Index Russia | 1,172 0.66 | |
Basic Materials Brazil | 5,814 0.49 | |
Swiss Leader Price Switzerland | 1,857 0.69 | |
Fondo Mutuo ETF Chile | 1,416 0.34 | |
Athens General Comp Greece | 1,449 0.06 | |
Stock Exchange Of Thailand | 1,361 0.27 | |
PX Prague Stock Czech Repub | 1,557 0.49 | |
THE PHILIPPINE STOCK Philippines | 6,573 1.01 | |
WIG 30 Poland | 3,051 0.89 | |
BIST Electricity Turkey | 592.91 0.41 |
Investing Ideas
In addition to having Blueprint Medicines in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Thematic Opportunities
Explore Investment Opportunities
Compare Blueprint Medicines
Compare Blueprint Medicines To Peers
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.